1. Home
  2. NEUP vs EVAX Comparison

NEUP vs EVAX Comparison

Compare NEUP & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$3.65

Market Cap

23.1M

Sector

N/A

ML Signal

HOLD

Logo Evaxion Biotech

EVAX

Evaxion Biotech

N/A

Current Price

$3.38

Market Cap

25.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEUP
EVAX
Founded
1996
2008
Country
United States
Denmark
Employees
8
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.1M
25.8M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NEUP
EVAX
Price
$3.65
$3.38
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$21.00
$11.67
AVG Volume (30 Days)
99.7K
24.9K
Earning Date
05-23-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$328.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.19
$2.45
52 Week High
$21.31
$12.15

Technical Indicators

Market Signals
Indicator
NEUP
EVAX
Relative Strength Index (RSI) 29.63 41.70
Support Level N/A $2.95
Resistance Level $4.56 $3.62
Average True Range (ATR) 0.35 0.27
MACD -0.09 0.02
Stochastic Oscillator 13.76 28.89

Price Performance

Historical Comparison
NEUP
EVAX

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

About EVAX Evaxion Biotech

Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.

Share on Social Networks: